Notizie AIOM – anno XVII
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Niraparib, an inhibitor of poly(adenosine diphosphate -ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence ...Leggi tutto
Four-week limit for use of high-strength estradiol creams
Oct 4, 2019 - EMA’s safety committee (PRAC) has recommended limiting the use of high-strength creams containing 100 micrograms/gram (0.01%) of estradiol to a single treatment period of up to 4 weeks. This measure is intended to minimise the risk of side effects caused ...Leggi tutto
EMA Management Board: highlights of October 2019 meeting
Oct 4, 2019 - At its 3 October 2019 meeting in Amsterdam, the European Medicines Agency's Management Board elected Lorraine Nolan as vice-chair of the Board for a three-year period. Dr Nolan is Chief Executive of the Health Products Regulatory Agency (HPRA) in Ireland, a ...Leggi tutto
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
The large-scale genetic profiling of tumours can identify potentially actionable molecular variants for which approved anticancer drugs are available. However, when patients with such variants are treated with drugs outside of their approved label, successes and failures ...Leggi tutto
New ASCO System Confronts Lack of EHR Interoperability
Oct 3, 2019 - With the recent launch of a free, open-source system for standardizing the electronic storage of patient records, the American Society of Clinical Oncology (ASCO) hopes to improve information flow across electronic health record (EHR) platforms and curtail ...Leggi tutto
FDA Updates Neratinib Label in HER2+ Breast Cancer
Oct 3, 2019 - The FDA has approved a labeling supplement for neratinib for the extended adjuvant treatment of patients with HER2-positive early-stage breast cancer. The labeling supplement includes safety information based on interim results of the phase II CONTROL trial ...Leggi tutto